Disagreement FDA and EMA on RSV Maternal Vaccination: Possible Consequence for Global Mortality-Reference-Cited by-同舟云学术

Disagreement FDA and EMA on RSV Maternal Vaccination: Possible Consequence for Global Mortality

Published:2023-10-11 Issue:1 Volume:43 Page:e1-e2
ISSN:0891-3668
Container-title:Pediatric Infectious Disease Journal
language:en
Short-container-title:

Author:

Willemsen Joukje E.¹²^ORCID,Borghans José A. M.¹^ORCID,Bont Louis J.²^ORCID,Drylewicz Julia¹^ORCID

Affiliation:

1. From the Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands

2. Division of Infectious Diseases, Department of Pediatrics, University Medical Centre Utrecht, Utrecht, the Netherlands.

Abstract

The European Medicines Agency and the US Food and Drug Administration have recently approved a maternal vaccine for respiratory syncytial virus. The US Food and Drug Administration limits vaccination to later in pregnancy. Mathematical modeling demonstrates that this vaccination window may reduce the global mortality impact of the vaccine by 12%. Policymakers should carefully consider vaccine risks and benefits to safeguard vulnerable infants effectively.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health

Reference3 articles.

1. Bivalent prefusion f vaccine in pregnancy to prevent RSV illness in infants.;Kampmann;N Engl J Med,2023

2. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.;Li;Lancet,2022

3. Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: a mathematical modeling study.;Willemsen;Vaccine X,2023